158 related articles for article (PubMed ID: 32839531)
1. Integrated proteomics and metabolomics reveals the comprehensive characterization of antitumor mechanism underlying Shikonin on colon cancer patient-derived xenograft model.
Chen Y; Ni J; Gao Y; Zhang J; Liu X; Chen Y; Chen Z; Wu Y
Sci Rep; 2020 Aug; 10(1):14092. PubMed ID: 32839531
[TBL] [Abstract][Full Text] [Related]
2. Uncovering the antitumor effects and mechanisms of Shikonin against colon cancer on comprehensive analysis.
Chen Y; Si L; Zhang J; Yu H; Liu X; Chen Y; Wu Y
Phytomedicine; 2021 Feb; 82():153460. PubMed ID: 33476976
[TBL] [Abstract][Full Text] [Related]
3. Integration of Transcriptomics and Metabolomics Reveals the Antitumor Mechanism Underlying Shikonin in Colon Cancer.
Chen Y; Gao Y; Yi X; Zhang J; Chen Z; Wu Y
Front Pharmacol; 2020; 11():544647. PubMed ID: 33281602
[TBL] [Abstract][Full Text] [Related]
4. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways.
Yang Q; Ji M; Guan H; Shi B; Hou P
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1909-17. PubMed ID: 24106286
[TBL] [Abstract][Full Text] [Related]
5. Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling.
Li MY; Mi C; Wang KS; Wang Z; Zuo HX; Piao LX; Xu GH; Li X; Ma J; Jin X
Chem Biol Interact; 2017 Aug; 274():58-67. PubMed ID: 28684144
[TBL] [Abstract][Full Text] [Related]
6. Shikonin inhibits cancer cell cycling by targeting Cdc25s.
Zhang S; Gao Q; Li W; Zhu L; Shang Q; Feng S; Jia J; Jia Q; Shen S; Su Z
BMC Cancer; 2019 Jan; 19(1):20. PubMed ID: 30616572
[TBL] [Abstract][Full Text] [Related]
7. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway.
Wang Y; Zhou Y; Jia G; Han B; Liu J; Teng Y; Lv J; Song Z; Li Y; Ji L; Pan S; Jiang H; Sun B
Biochem Pharmacol; 2014 Apr; 88(3):322-33. PubMed ID: 24522113
[TBL] [Abstract][Full Text] [Related]
8. Successful in vivo hyperthermal therapy toward breast cancer by Chinese medicine shikonin-loaded thermosensitive micelle.
Su Y; Huang N; Chen D; Zhang L; Dong X; Sun Y; Zhu X; Zhang F; Gao J; Wang Y; Fan K; Lo P; Li W; Ling C
Int J Nanomedicine; 2017; 12():4019-4035. PubMed ID: 28603416
[TBL] [Abstract][Full Text] [Related]
9. Shikonin induces colorectal carcinoma cells apoptosis and autophagy by targeting galectin-1/JNK signaling axis.
Zhang N; Peng F; Wang Y; Yang L; Wu F; Wang X; Ye C; Han B; He G
Int J Biol Sci; 2020; 16(1):147-161. PubMed ID: 31892852
[TBL] [Abstract][Full Text] [Related]
10. Shikonin inhibits proliferation of melanoma cells by MAPK pathway-mediated induction of apoptosis.
Lee JH; Han SH; Kim YM; Kim SH; Yoo ES; Woo JS; Jung GH; Jung SH; Kim BS; Jung JY
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33403388
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the antitumor effects of PP242 in a colon cancer xenograft mouse model using comprehensive metabolomics and lipidomics.
Rashid MM; Lee H; Jung BH
Sci Rep; 2020 Oct; 10(1):17523. PubMed ID: 33067464
[TBL] [Abstract][Full Text] [Related]
12. Regulations of miR-183-5p and Snail-Mediated Shikonin-Reduced Epithelial-Mesenchymal Transition in Cervical Cancer Cells.
Tang Q; Liu L; Zhang H; Xiao J; Hann SS
Drug Des Devel Ther; 2020; 14():577-589. PubMed ID: 32103900
[TBL] [Abstract][Full Text] [Related]
13. Deoxyshikonin isolated from
Zhu Y; Zhong Y; Long X; Zhu Z; Zhou Y; Ye H; Zeng X; Zheng X
Pharm Biol; 2019 Dec; 57(1):412-423. PubMed ID: 31230505
[No Abstract] [Full Text] [Related]
14. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
Woo JK; Kang JH; Jang YS; Ro S; Cho JM; Kim HM; Lee SJ; Oh SH
Oncol Rep; 2015 Apr; 33(4):1947-55. PubMed ID: 25672292
[TBL] [Abstract][Full Text] [Related]
15. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
[TBL] [Abstract][Full Text] [Related]
16. SIRT2 mediated antitumor effects of shikonin on metastatic colorectal cancer.
Zhang LL; Zhan L; Jin YD; Min ZL; Wei C; Wang Q; Chen YJ; Wu QM; Hu XM; Yuan Q
Eur J Pharmacol; 2017 Feb; 797():1-8. PubMed ID: 28088387
[TBL] [Abstract][Full Text] [Related]
17. γ-Aminobutyric acid inhibits the proliferation and increases oxaliplatin sensitivity in human colon cancer cells.
Song L; Du A; Xiong Y; Jiang J; Zhang Y; Tian Z; Yan H
Tumour Biol; 2016 Nov; 37(11):14885-14894. PubMed ID: 27644246
[TBL] [Abstract][Full Text] [Related]
18. Shikonin induces apoptosis and G0/G1 phase arrest of gallbladder cancer cells via the JNK signaling pathway.
Zhai T; Hei Z; Ma Q; Liang H; Xu Y; Zhang Y; Jin L; Han C; Wang J
Oncol Rep; 2017 Dec; 38(6):3473-3480. PubMed ID: 29039581
[TBL] [Abstract][Full Text] [Related]
19. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
[TBL] [Abstract][Full Text] [Related]
20. Metformin Inhibits the Urea Cycle and Reduces Putrescine Generation in Colorectal Cancer Cell Lines.
Zhang T; Hu L; Tang JF; Xu H; Tian K; Wu MN; Huang SY; Du YM; Zhou P; Lu RJ; He S; Xu JM; Si JJ; Li J; Chen DL; Ran JH
Molecules; 2021 Apr; 26(7):. PubMed ID: 33915902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
